Coronary artery disease
Impact of Clopidogrel on Suppression of Circulating Levels of Soluble CD40 Ligand in Patients With Unstable Angina Undergoing Coronary Stenting

https://doi.org/10.1016/j.amjcard.2005.08.023Get rights and content

This study investigated whether a regimen that comprised a loading dose of 300 mg of clopidogrel followed by 75 mg/day could significantly suppress circulating levels of soluble CD40 ligand (sCD40L) in patients who had unstable angina and underwent coronary stenting. Study results showed that the clopidogrel loading dose substantially decreased the circulating level of sCD40L at 24 hours after stenting (p <0.0001). Combined with aspirin, 75 mg/day of clopidogrel continuously decreased sCD40L levels after coronary stenting.

References (20)

There are more references available in the full text version of this article.

Cited by (28)

  • Prasugrel as opposed to clopidogrel improves endothelial nitric oxide bioavailability and reduces platelet-leukocyte interaction in patients with unstable angina pectoris: A randomized controlled trial

    2017, International Journal of Cardiology
    Citation Excerpt :

    Increased blood levels of sCD40L are found in unstable angina patients [39] and associated with higher cardiovascular risk in ACS [40]. Various studies provide evidence that platelet inhibition with clopidogrel reduces sCD40L [9,26,41,42] and RANTES levels [9]. The observations in our study are partly in line with previous data, since we also observed a decrease in sCD40L and RANTES in both treatment arms, although it did only reach statistical significance in the prasugrel group suggesting a relevant reduction in platelet-mediated inflammation.

  • The CD40/CD40L system: A new therapeutic target for disease

    2013, Immunology Letters
    Citation Excerpt :

    Clopidogrel mitigates platelet aggregation by inhibiting the ADP receptor, and it has been widely used in acute coronary syndrome and in percutaneous coronary intervention patients. Presumably, as a consequence of inhibiting the ADP receptor, clopidogrel also decreases plasma sCD40L levels induced by activated platelets [30], thereby delaying the development of AS. Unexpectedly, it has been reported that CD40L expression on platelets increased rather decreased in CAD patients who have had pharmacotherapy with clopidogrel (75 mg/d) and aspirin (325 mg/d) for one year [31].

  • The CD40/CD40 Ligand System. Linking Inflammation With Atherothrombosis

    2009, Journal of the American College of Cardiology
    Citation Excerpt :

    As activated platelets are the main source of circulating sCD40L, antiplatelet agents were among the first drugs studied for their CD40L-lowering properties. Clopidogrel, which acts via adenosine diphosphate receptor inhibition, completely inhibits sCD40L release from adenosine diphosphate-stimulated platelets; patients under clopidogrel treatment exhibit reduced CD40L platelet expression and circulating sCD40L levels (54). Moreover, it was also found that both short- and long-term treatment with clopidogrel significantly reduces sCD40L levels in patients with stable CAD (55), although a recent study demonstrated enhanced expression of CD40L on platelets surface after 1 year of treatment with clopidogrel 75 mg/day plus aspirin 325 mg/day in patients with CAD (56).

View all citing articles on Scopus
View full text